Risk of endometrial cancer in relation to medical conditions and medication use
- PMID: 19383893
- PMCID: PMC2763278
- DOI: 10.1158/1055-9965.EPI-08-0936
Risk of endometrial cancer in relation to medical conditions and medication use
Abstract
We studied the relation of medical conditions related to obesity and medications used for these conditions with endometrial cancer. We also investigated the association of other medical conditions and medications with risk. This U.S. population-based case-control study included 469 endometrial cancer cases and 467 controls. Information on putative risk factors for endometrial cancer was collected through personal interviews. We asked women about their medical history and medications used for six months or longer and the number of years each medication was taken. Risk was strongly associated with increasing obesity (P for trend < 0.001). Among the conditions related to obesity, and after adjustment for age, body mass index, and other risk factors and conditions, uterine fibroids were independently related to an increased cancer risk [adjusted odds ratio (OR), 1.8; 95% confidence interval (95% CI), 1.2-2.5]. Although hypertension was not significantly related to endometrial cancer after adjustment for age and body mass index, the use of thiazide diuretics was independently associated with increased risk (OR, 1.8; 95% CI, 1.1-3.0). Anemia was associated with decreased risk (OR, 0.6; 95% CI, 0.5-0.9). Use of nonsteroidal anti-inflammatory drugs was related to a decreased risk (OR, 0.7; 95% CI, 0.5-0.97). To our knowledge, the observation about thiazide diuretics is novel and requires confirmation in other studies and populations.
Conflict of interest statement
Conflict of interest statement: Joan Fortuny is currently an employee at Novartis Pharmaceutical. The study and manuscript were conducted and prepared before the author’s joining to Novartis Pharmaceutical. Novartis has not participated in any stage of the study preparation, funding or conduct, and has not had access to the study data, manuscripts in preparation, or the final version of the manuscript. The other authors report no conflict of interest for the present study.
References
-
- Ferlay, Bray F, Pisani P, Parkin D. GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide. 5. IARC Press; 2001.
-
- Modugno F, Ness RB, Chen C, Weiss NS. Inflammation and endometrial cancer. Cancer Epidemiol Biomarkers Prev. 2005;14:2840–7. - PubMed
-
- Vaskivuo TE, Stenback F, Tapanainen JS. Apoptosis and apoptosis related factors Bcl-2, Bax, tumor necrosis factor-α, and NF-κβ in human endometrial hyperplasia and carcinoma. Cancer. 2002;95:1463–71. - PubMed
-
- Cao QJ, Einstein MH, Anderson PS, Runowicz CD, Balan R, Jones JG. The expression of cyclooxigenase-1 and -2 in proliferative endometruim and endometrial carcinoma. Int J Gynecol Pathol. 2002;21:147–54. - PubMed
-
- Jeon YT, Kang S, Kang DH. Cyclooxygenase-2 and p53 expressions in endometrial cancer. Cancer Epidemiol Biomarkers Prev. 2004;13:1538–42. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical